LEMTRADA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug LEMTRADA contains one active pharmaceutical ingredient (API):

1 Alemtuzumab UNII 3A189DH42V - ALEMTUZUMAB

Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52) expressed primarily on the surface of normal and malignant peripheral blood B and T cell lymphocytes. Alemtuzumab acts through antibody-dependent cellular cytolysis and complement-mediated lysis following cell surface binding to CD52, a cell surface antigen present at high levels on T (CD3+) and B (CD19+) lymphocytes, and at lower levels on natural killer cells, monocytes, and macrophages. Read about Alemtuzumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LEMTRADA Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AG06	Alemtuzumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10228H, 10232M, 10243D, 10246G
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 576720030060017
Country: CA	Health Products and Food Branch	Identifier(s): 02418320
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 21-MBE-0415
Country: EE	Ravimiamet	Identifier(s): 1625969
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 112869001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 165070
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 245619
Country: HK	Department of Health Drug Office	Identifier(s): 64543
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7616
Country: IT	Agenzia del Farmaco	Identifier(s): 043027010
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1071216
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 99546
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100304487
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64873001
Country: SG	Health Sciences Authority	Identifier(s): 14919P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699809779228
Country: US	FDA, National Drug Code	Identifier(s): 58468-0200